RxDoctor Payments Data

Roger Ng

Cardiovascular Disease · Tacoma, WANPI 1407992076

Payments from drug & device makers

$782in general payments, 2019–2025

Across 23 payments — averaging $34.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$217
  • Edwards Lifesciences$164
  • Baxter Healthcare$91
  • Bayer$44
  • Boston Scientific$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$782 in reported general payments places this provider in the 50th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$253,039
Medicare patients
1,028
Services billed
2,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$114,613
Repatha SureclickEvolocumab34$29,601
XareltoRivaroxaban24$29,082
EntrestoSacubitril/Valsartan29$17,690
Ranolazine ErRanolazine16$2,897
Sodium Chloride0.9 % Sodium Chloride31$2,214
Atorvastatin Calcium156$1,644
Rosuvastatin Calcium61$993
Metoprolol Succinate70$930
Losartan Potassium78$671
Bisoprolol Fumarate30$657
Metoprolol Tartrate79$478
Hydralazine Hcl42$453
Ezetimibe20$443
Doxazosin Mesylate23$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$14$17,69029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →